The iQ Group Global
85 Castlereagh Street
Level 9
Sydney
NSW
2000
Australia
Tel: +61 2 8239 5400
Website: https://theiqgroupglobal.com/
About The iQ Group Global
We provide a turnkey solution for life sciences companies, spanning from corporate advisory and investment banking, through to research, development, commercialisation and sales. The iQ Group Global facilitates an end-to-end solution along the drug lifecycle creating the medicines of tomorrow.
Our life science and pharmaceutical practice collaborate with scientists the world over: Identifying and owning Intellectual Property, creating and executing drug development plans from discovery to market. From simple chemical entities to complex genetic therapeutics and beyond, we are creating the medicines of the future.
In addition…
Our dedicated investment banking business transforms biotech from an alternative investment option to a requisite mainstream capital market asset. We design and market innovative structured financial products and solutions. These provide entry and exit, investment and divestment, in the 12 or more year drug development cycle.
3 articles about The iQ Group Global
-
The iQ Group Global secures worldwide license for Harvard University’s eRapid technology for at-home diagnostic testing
3/8/2022
Antisoma Therapeutics Pty. Ltd. announced it has received a worldwide license from Harvard’s Office of Technology Development to commercialize diagnostic technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University, with exclusivity in the fields of respiratory viral illnesses, cancer, and immune/allergic disease.
-
The iQ Group Global Appoints World-Renowned Chemist to the Board of Member Company, GBS Inc.
12/9/2019
A biosensor diagnostic company based in New York, GBS Inc. is commercializing the patent-protected Saliva Glucose Biosensor in the Asia Pacific region, where there are more people living with diabetes than anywhere else in the world.
-
The iQ Group Global acquires new anticancer drug platform from University of Texas
9/16/2019
Added a novel anticancer drug platform to its portfolio that has the ability to develop a range of cancer therapeutics.